Ascentage Pharma
800 King Farm Blvd.
Suite 300
Rockville
MD
20850
United States
Website: http://www.ascentagepharma.com/
161 articles about Ascentage Pharma
-
ASH 2022 | Ascentage Pharma to Present Initial Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Combination with BTK Inhibitors for the Treatment of R/R CLL/SLL, Including an ORR of 98%, in an Oral Report at the ASH Annual Meeting
11/3/2022
Ascentage Pharma announced that the initial results from a global Phase II study of the company's Bcl-2-selective inhibitor, lisaftoclax, as a monotherapy or in combination regimens for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, have been selected for an oral presentation at the 64th American Society of Hematology Annual Meeting.
-
ASH 2022 | Ascentage Pharma to Present Data of Olverembatinib (HQP1351) in Three Oral Reports, Including the First Dataset from the First US Study, at the ASH Annual Meeting
11/3/2022
Ascentage Pharma announced that the updated results from three studies of the company's novel drug candidate, olverembatinib, have been selected for oral presentations at the 64th American Society of Hematology Annual Meeting.
-
AASLD 2022 | Ascentage Pharma to Announce Results from First-in-Human Study of IAP Antagonist APG-1387 in an Oral Report at the AASLD Annual Meeting
10/19/2022
Ascentage Pharma (6855.HK) today announced that it will release results from the Phase I first-in-human study of APG-1387, the company's investigational inhibitor of apoptosis protein (IAP) antagonist, in patients with chronic hepatitis B (CHB), in an oral presentation at the 73th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2022).
-
Ascentage Pharma Announces 2022 Interim Results
8/26/2022
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2022 interim results.
-
Ascentage Pharma and Tanner Pharma Group Initiate a Global Innovative Named Patient Program
7/25/2022
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Tanner Pharma Group ("Tanner Pharma"), a global pharmaceutical services provider of specialty access solutions, have jointly launched an innovative Named Patient Program (NPP) for olverembatinib.
-
Ascentage Pharma Announces Clinical Trial Application for Olverembatinib (HQP1351) Approved in Canada
7/21/2022
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma's novel drug candidate, olverembatinib (HQP1351).
-
Ascentage Pharma and Innovent Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
7/19/2022
Ascentage Pharma and Innovent Biologics, Inc. announce that the Center for Drug Evaluation of China National Medical Products Administration has accepted and granted Priority Review designation to a New Drug Application that will support the full approval of olverembatinib in patients with chronic-phase chronic myeloid leukemia who are resistant and/or intolerant of first- and second-generation tyrosine kinase inhibitors.
-
Innovent and Ascentage Pharma Announce the China NMPA Accepted and Granted Priority Review Designation to a New Drug Application for Olverembatinib for the Treatment of Drug-Resistant CML
7/19/2022
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), and Ascentage Pharma (6855.HK), today announce that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has accepted and granted Priority Review designation[1].
-
Ascentage Pharma Announces IND Clearance by the US FDA for First-in-Human Study of Novel EED Inhibitor APG-5918
6/30/2022
Ascentage Pharma announced that its novel inhibitor of the embryonic ectoderm development protein, APG-5918, has been cleared by the US Food and Drug Administration to enter a first-in-human study that will assess the safety, pharmacokinetics, and preliminary efficacy of APG-5918 in patients with solid tumors or hematologic malignancies.
-
EHA 2022 | Ascentage Pharma Releases Encouraging Results of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients with Relapsed/Refractory Non-Hodgkin Lymphoma
6/13/2022
Ascentage Pharma announced that it has released results from a Phase I study of the company's novel Bcl-2-selective inhibitor lisaftoclax in Chinese patients with relapsed/refractory non-Hodgkin lymphoma at the 2022 European Hematology Association Hybrid Congress.
-
CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.
-
ASCO 2022 | The First Dataset of Olverembatinib (HQP1351) in Patients with GIST Demonstrates Therapeutic Potential with a Clinical Benefit Rate of 83.3%
6/7/2022
Ascentage Pharma announced that it has released the latest results from a Phase Ib/II study of the third-generation tyrosine kinase inhibitor olverembatinib in patients with metastatic gastrointestinal stromal tumor who were resistant to or failed prior TKI treatment, in a Poster Discussion session at the 58th American Society of Clinical Oncology Annual Meeting.
-
ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies
6/7/2022
scentage Pharma announced that it has released the updated results from a Phase II study of the MDM2-p53 inhibitor alrizomadlin plus pembrolizumab in adults and children with various solid tumors in a Poster Discussion session at the 58th American Society of Clinical Oncology Annual Meeting.
-
ASCO 2022 | Ascentage Pharma Releases Updated Data Demonstrating Lisaftoclax's (APG-2575) Therapeutic Potential in Patients with R/R CLL/SLL
6/7/2022
Ascentage Pharma (6855.HK), today announced that it has released the updated results from a Phase Ib/II study of the Bcl-2 inhibitor lisaftoclax (APG-2575) in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL) in a Poster Presentation at the 58th American Society of Clinical Oncology (ASCO) Annual Meeting.
-
ASCO 2022 | Ascentage Pharma Releases for the First Time Results of its FAK/ALK/ROS1 inhibitor APG-2449 Demonstrating Safety and Efficacy in Patients with Advanced NSCLC
6/7/2022
Ascentage Pharma (6855.HK), today announced that it has released the results from its Phase I first-in-human (FIH) study of the company's novel FAK inhibitor and third-generation ALK/ROS1 tyrosine kinase inhibitor (TKI) APG-2449.
-
ASCO 2022 | Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development
5/27/2022
Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that its seven clinical abstracts selected by the 2022 American Society of Clinical Oncology Annual Meeting, of which six were selected for presentations and one was selected for publication-only, have been published on the ASCO's website.
-
Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine
5/18/2022
Ascentage Pharma (6855.HK), today announced that a new preclinical study, conducted by the researchers from Fred Hutchinson Cancer Research Center, Seattle, suggests the therapeutic potential of olverembatinib (HQP1351) in inhibiting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron-mediated cytokine release.
-
ASCO 2022 | Ascentage Pharma to Present Data from Seven Clinical Studies at the 2022 American Society of Clinical Oncology Annual Meeting
4/28/2022
Ascentage Pharma announced that updated results from seven studies involving the company's five novel drug candidates will be presented at the 2022 American Society of Clinical Oncology Annual Meeting.
-
AACR 2022 | Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022
4/13/2022
Ascentage Pharma announced that it has presented the latest results from six preclinical studies of the company's five investigational drug candidates: the Bcl-2 inhibitor lisaftoclax and the MDM2-p53 inhibitor alrizomadlin, two key candidates in the company's apoptosis-targeted pipeline, as well as the FAK inhibitor APG-2449, the EED inhibitor APG-5918 and the KRAS inhibitor APG-1842, at the 2022 American Association for Cancer Research Annual Meeting.
-
Ascentage Pharma's MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma
3/21/2022
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that its novel MDM2-p53 inhibitor, alrizomadlin (APG-115), was granted a Rare Pediatric Disease (RPD) designation by the US Food and Drug Administration (FDA), for the treatment of neuroblastoma.